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Abstract
A variety of genetic alterations and gene expression
changes are involved in the pathogenesis of bladder
tumors. To explore expression changes in 4-hydroxy-
butyl(butyl)nitrosamine–induced rat bladder tumors,
microarray analysis was performed. Analysis yielded
1,138 known genes and 867 expressed sequence tags
that were changed when comparing tumors to normal
rat epithelia. Altered genes included cell cycle–related
genes, EGFR-Ras signaling genes, apoptosis genes,
growth factors, and oncogenes. Using the pathway
visualization tool GenMAPP, we found that these
genes can be grouped along several pathways that
control apoptosis, cell cycle, and integrin-mediated
cell adhesion. When comparing current data with pre-
vious mouse bladder tumor data, we found that > 280
of the same known genes were differentially expressed
in both mouse and rat bladder tumors, including cell
cycle–related genes, small G proteins, apoptosis
genes, oncogenes, tumor-suppressor genes, and
growth factors. These results suggest that multiple
pathways are involved in rat bladder tumorigenesis,
and a commonmolecularmechanismwas found in both
rat and mouse bladder tumors.
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Introduction
Bladder cancer is the fifthmost common cancer in theUnited
States and is associated with exposure to cigarette smoke.
Approximately 15% of bladder tumors evolve into invasive
tumors after infiltration through the basement membrane.
Patients with muscle-invasive disease are at high risk for
recurrence, progression, and metastasis. Although early-
stage bladder cancer can be treated surgically, the rate
of recurrence is quite high [1]. Significant progress has
been made in understanding the underlying molecular and
genetic events in bladder cancer. Numerous markers have
been described to correlate, to some extent, tumor stage
and the prognosis of patients with bladder cancer [2].
Although a number of markers have been identified, there
remains a need for the development of reliable additional
markers that can provide information regarding diagnosis
and prognosis. In addition, the identification of specific pro-
teins that might be favorable targets for treatment is of some
interest. Expression profiling with high-throughput DNA micro-
arrays has the potential of providing critical clues. Our pre-
vious study on mouse bladder tumors revealed that activation
of the EGFR-Ras, G13, and TGF-b pathways, and increased
cell proliferation appear to play important roles during mouse
bladder tumorigenesis.
There are two primary chemically induced models of urinary
bladder cancers in rodents. Both employ repeated intragastric
administration of 4-hydroxybutyl(butyl)nitrosamine (OH-BBN)
to induce bladder cancers in either mice or rats [3,4]. Bladder
cancers typically have a mixed histology, showing elements
of both transitional and squamous cells. Investigators have
found a relatively low frequency of rasmutation in these cancers
[5]. However, roughly 50% of these tumors develop p53 muta-
tions [6]—a percentage similar to that found in humans. There
has been further characterization of these tumors for various
gene products, including mutations in the epidermal growth
factor receptor (EGFR) kinase activation loop [7]. Similar to
human bladder tumors, these tumors tend to show over-
expression of EGFR and amphiregulin. Other genetic changes
include ras, erb-B2, and EGFR. The transforming potential of
ras is due to mutation, whereas EGFR and erb-B2 are over-
expressed in transformed cells. Reported frequencies of H-ras
point mutations with a glycine-to-valine substitution in codon
12 in bladder neoplasms vary widely from 0% to 45% between
studies [8–11]. Recently, several means of suppressing ras ac-
tivity, including inhibitors of ras signal transduction and a ras-
suppressor mutant, have been reported [12]. Overexpression
of EGFR or erb-B2 and ras mutations results in constitutive
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MAPK activation [13], and this correlates with muscular
invasion and extent of tumor invasion [2]. Almost all advanced
bladder carcinomas exhibit alterations in cell cycle genes
(e.g., decreases in pRb or p16INK4a, or increases in cyclin D1
expression preferentially occurring in earlier stages) [14,15].
In this study, we employed Affymetrix GeneChips
(Affymetrix, Santa Clara, CA) representing > 30,000 genes
and expressed sequence tags (ESTs) to identify differentially
expressed genes in rat bladder tumors. The objectives of the
study were: 1) to detect and identify differential gene ex-
pression profiles in rat bladder tumors; 2) to help elucidate
the underlying mechanisms of rat bladder tumorigenesis;
and 3) to compare the present results with our previous data
on mouse bladder tumors to identify common genes and
pathways that may be particularly relevant to the mechanism
of carcinogenesis in the bladder.
Materials and Methods
Rat Bladder Tumors
Rats were obtained from Harlan Sprague–Dawley, Inc.
(Indianapolis, IN), at 28 days of age and were housed in
polycarbonate cages (five per cage). The animals were kept
in a lighted room 12 hours each day and maintained at
22 ± 0.5jC. Teklad 4% mash diet (Harlan Teklad, Madison,
WI) and tap water were provided ad libitum. At 56 days of
age, mice received the first of 12 weekly gavage treatments
with OH-BBN (TCI America, Portland, OR). Each 7.5-mg
dose was dissolved in 0.1 ml of ethanol/water (25:75). Rats
(unless sacrificed early because of a large palpable bladder
mass) were sacrificed 8 months following the first OH-BBN
treatment. Bladder tumors were removed and frozen for
subsequent molecular assays. A portion of each tumor
was fixed and processed for routine paraffin embedding,
cut into 5-mm sections, and mounted for hematoxylin–eosin
staining for histopathology. All bladder tumors used in this
study were diagnosed as bladder carcinomas, with a mixed
histology showing elements of both transitional and squa-
mous cells. Both bladder tissues and normal bladder epi-
thelia came from age-matched controls.
RNA Isolation and Amplification
To isolate bladder epithelia, we separated the epithelia
from the stroma and muscle tissues by cutting the bladder
into half and scraping off the epithelium. Total RNA from
normal bladder epithelia and bladder tumors were isolated by
Trizol (Invitrogen, Carlsbad, CA) and purified using the
RNeasy Mini Kit and RNase-free DNase Set (QIAGEN,
Valencia, CA) according to the manufacturer’s protocols.
In vitro transcription-based RNA amplification was then per-
formed on each sample. cDNA for each sample was synthe-
sized using a Superscript cDNA Synthesis Kit (Invitrogen)
and a T7-(dT)24 primer, 5V-GGCCAGTGAATTGTAATACGA-
CTCACTATAGGGAGGCGG-(dT)24-3V. cDNA were cleaned
using phase-lock gels (Fisher cat ID E0032005101) and
phenol/chloroform extraction. Then, biotin-labeled cRNA
were transcribed in vitro from cDNA using a BioArray High
Yield RNA Transcript Labeling Kit (ENZO Biochem, New
York, NY) and purified again using the RNeasy Mini Kit.
Affymetrix GeneChip Probe Array and Quantitative
Confirmation by Real-Time Polymerase Chain
Reaction (PCR)
The labeled cRNA were applied to Affymetrix Rat 230
2.0 GeneChips (Affymetrix) according to the manufacturer’s
recommendations. Every gene or EST is represented by a
probe set consisting of approximately 16 probe pairs (oligo-
nucleotides) of 25-mer oligonucleotides. One sequence of a
probe pair represents the complementary strand of the
target sequence, whereas the other has a 1-bp mismatch at
the central basepair position. This mismatch sequence
serves as an internal control for the specificity of hybridiza-
tion. To evaluate the reliability of array results, genes were
randomly selected from the genes detected in the micro-
array assay for further confirmation by real-time PCR, as
previously described [16]. The large number of differentially
expressed genes led us to take a further quality control step
in which the distribution of fold changes was examined.
Cluster and GenMAPP
Array normalization and gene expression estimates were
obtained using Affymetrix Microarray Suite 5.0 software
(MAS5). Array mean intensities were scaled to 1500. These
estimates formed the basis for statistical testing. Differential
expression was determined using the combined basis of
t-test with P < .05 and fold changes (either up or down) of
> 2-fold. Genes meeting both criteria were called positive
for differential expression. Hierarchical clustering was then
performed as follows. For selected genes, expression in-
dexes were transformed across samples to an N(0,1) distri-
bution using a standard statistical Z-transform. These values
were put into the GeneCluster program of Eisen et al. [17],
and genes were clustered using average linkage and corre-
lation dissimilarity. Signal transduction pathways, metabolic
pathways, and other functional groupings of genes were
evaluated for differential regulation using the visualization
tool GenMAPP [18]. We imported the statistical results of
our data set into the program and used GenMAPP to illus-
trate pathways containing differentially expressed genes.
Protein Isolation and Two-Dimensional (2D) Protein Gel
Protein was isolated from epithelia and tumors, and
proteomic analysis was performed using 2D differential gel
electrophoresis. Protein samples from five normal and five
tumor-bearing animals were paired. The protein samples
(50 mg) were labeled substoichiometrically with one of two
N-hydroxysuccinimide cyanine dyes (GE Healthcare Bio-
sciences, Piscataway, NJ). Immobilized pH gradient strips
(24 cm; pH 3–11, nonlinear) were rehydrated with the
samples (pooled normal and tumor). The first dimension of
isoelectric focusing was performed for 75 kV h in Protean
IEF Cell System (Bio-Rad, Hercules, CA). The strips were
equilibrated and positioned on a 10% to 20% gradient
sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis gel. Resolved protein imageswere acquired on a Typhoon
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9400 scanner (GE Healthcare Biosciences). Relative quan-
tification of matched gel features was performed using
Decyder-DIA software (GE Healthcare Biosciences). Se-
lected gel features were excised and digested in situ
with trypsin. The resulting peptide pools were analyzed
by tandem mass spectrometry using both matrix assisted
layer desorption/ionization tandem time-of-flight mass spec-
trometer (MALDI-TOF/TOF) (Proteomics 4700; Applied Bio-
systems, Framingham, MA, and Toronto, Ontario, Canada)
and liquid chromatography– tandem mass spectrometer
(LC–MS/MS) (LTQ-FTMS; Thermolelectron, San Jose, CA)
instruments. Peptide fragmentation spectra were processed
using Data Explorer v. 4.5 and Analyst software (Applied Bio-
systems, Foster City, CA), and MASCOT v. 1.9 (Matrix Sci-
ences, London, UK).
Immunohistochemistry (IHC) Staining
Briefly, paraffin sections of rat normal and tumor bladders
(n = 5) were antigen-retrieved in citrate buffer for 20 min-
utes in a microwave. This was followed by blocking in normal
horse serum, and sections were incubated in primary anti-
body cyclin D1 (sc-450, 1:500; Santa Cruz Biotech, Santa
Cruz, CA) or annexin I (sc-12740, 1:50; Santa Cruz Biotech)
overnight at 4jC. The corresponding biotinylated second-
ary IgG (1:500) was used, and the sections were developed
by the ABC method (Vector Laboratories, Burlingame, CA)
with 3,3V-diaminobenzidine HCl as substrate.
Results
Gene Expression Profile in Bladder Tumors
Microarray data were compared for five rat bladder tu-
mors and their age-matched normal rat bladder epithelia.
The fold changes of gene expression were based on the ratios
of mean values between tumors and epithelium controls.
Two thousand five known genes and ESTs were found to
be differentially expressed in rat bladder tumors with a fold
change of z 2 and P < .05. Among them, 1,138 genes were
known genes, with 770 genes overexpressed and 368 genes
underexpressed in bladder tumors (Figure 1). Many of the
overexpressed genes were cancer-related genes belonging
to EGFR-Ras signaling, cell cycle, and apoptosis (Table 1).
Underexpressed genes included the Rab subfamily of genes,
tumor-suppressor genes, and genes encoding casein ki-
nases, cytochromeP450s, and RAR-related orphan receptors
(Table 2). These genes are involved in a broad range of differ-
ent pathways, including control of cell proliferation, differen-
tiation, cell cycle, signal transduction, and apoptosis. Tables 1
and 2 list selected genes that were changed in rat bladder
tumors. The Ras superfamily is a diverse group of small G
proteins participating in many cellular processes and widely
involved in tumorigenesis. In this study, many Ras superfamily
members were found to be abnormally expressed in bladder
tumors. Interestingly, Rab subfamily genes were under-
expressed (Table 2). All other Ras-related genes, such as
Ras,Rin,Rem,Rap,Rac,Rad, andRho, were overexpressed
in bladder tumors (Table 1). Many overexpressed genes in
tumors were cell cycle–related genes that promote entry into
cell cycle and mitosis. These include the following: Cdc2A,
Cdc20, and Cdc25B; cyclins A2, B1, B2, and D1; Cdkn2a,
Cdkn2c, Cdkn2d, and Cdkn3; MAD2; Polo-like kinases 1 and
4; andGadd45  and c (Table 1). Amore limited number of cell
cycle–related genes (e.g., cyclin M1, p57, and JunDP1) were
underexpressed in rat bladder tumors (Table 2). Interestingly,
these genes play important roles in cell cycle arrest and G1/S
and G2 checkpoints. The Kit, Maf, Fes, Myc, and Fyn onco-
genes were overexpressed in rat bladder tumors (Table 1),
whereas theWT1,BRCA2,Mycl1, andPak geneswere under-
expressed in rat bladder tumors (Table 2). Survivin, TNF, and
Bcl-2were also overexpressed in rat bladder tumors (Table 1).
Confirmation of Differentially Expressed Genes for Both
RNA and Protein Levels
With such a large number of differentially expressed genes,
we examined the distribution of fold changes to detect if any
large skew could account for the results. The distribution of
fold changes for differentially expressed genes is shown in
Figure 2A, and its symmetry suggests that no skew artifact is
present. We validated the differential expression of 15 genes
by real-time PCR. Thirteen of 15 genes were confirmed by
real-time PCR. The confirmation rate is > 86% at a cutoff of
two-fold change and (P < .05). The real-time PCR results of
these 13 genes agreed well with microarray data (Figure 2B).
We also examined several genes at protein level by 2D pro-
tein gel electrophoresis and IHC. The genes annexin A1 and
cyclin D1 were chosen for this analysis, and results are
presented in Figure 3. Both RNA and protein level changes
for these genes agreed well with initial microarray changes.
Differentially Expressed Genes Interpreted by GenMAPP
We introduced the differentially expressed genes found in
microarrays into GenMAPP. GenMAPP search revealed that
apoptosis, cell cycle, and integrin-mediated cell adhesion are
actively involved in bladder tumorigenesis, with expression
changes in multiple genes, each of which may play important
roles in the pathogenesis of bladder cancers. Figure 4
represents the genes differentially expressed in rat bladder
tumors involved in these signaling pathways.
Comparison of Differentially Expressed Genes Between
Rat and Mouse Bladder Tumors
We compared the differentially expressed genes from
both rat and mouse bladder tumors using gene expression
data from mouse bladder tumors [19]. Of 860 comparable
genes between rats andmice, there were 280 genes that had
the same tendency of expression changes in bothmouse and
rat bladder tumors. Selected genes were listed in Tables 1
and 2 andmarked with asterisks. Themajority of these genes
are cell cycle–related genes, ras small G proteins, and
apoptosis-related and growth factor–related genes.
Discussion
In this study, we have shown that microarray can be used to
enhance the search for the molecular pathogenesis of
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tumors. We found that inappropriate regulation of ras, cell
cycle, and apoptosis pathways may be the three major steps
in the tumorigenesis of rat bladdermalignancy. In addition, we
were able to identify a variety of genes whose expression was
highly increased independent of whether they are directly
involved in the mechanism of tumorigenesis in this model.
These highly modulated genes were also proved to be
changed at the protein level and may prove highly useful in
identifying early lesions and tumors in samples from urine or
serum. In addition, both these highly overexpressed genes
and many of the genes that are along the mechanistic
pathway may prove to be modulated by effective preventive
or therapeutic agents.
One group of genes found to be differentially expressed in
bladder tumors comprises cell cycle–related genes. Tumor
proliferation depends on the derangement of normal cell
cycle progression and control. Cell cycle–associated protein
complexes composed of cyclins and cyclin-dependent
kinases (CDKs) regulate normal cellular proliferation. Differ-
ent CDK–cyclin complexes cooperate to drive cells through
different phases of the cell cycle. Activation of CDK4 and
CDK6 by D-type cyclins is thought to be involved in progres-
sion through early G1. We observed an increased expression
of a number of CDK-related phosphatases. Thus, a variety of
cell cycle commitment genes, including cyclins,CDCs,Cdca,
GADD45s, Gas, Plks, Mad2, and Bub1, were found to be
overexpressed in bladder tumors. Increased levels of cyclin
D1 are associated with a wide variety of cancers, including
breast, colon, and lung cancers. We confirmed the increase
in cyclin D1 observed in microarrays both by reverse
transcription (RT) PCR and by IHC (Figure 3). These results
help to demonstrate the potential use of array analysis in
determining biomarkers that might be useful in the identifica-
tion of early lesions. Overall, the results are in agreement with
Figure 1. Comparison of bladder epithelia and whole bladder tissues as controls to bladder cancers. Among the 1138 known genes found to be differentially
expressed in rat bladder tumors compared with epithelia, 770 genes were overexpressed and 368 genes were underexpressed. Green indicates an expression
below the mean value for the gene, black indicates an expression near the mean, and red indicates an expression above the mean.
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Table 1. Selected Genes Whose Expression Is Upregulated in Rat Bladder Tumors Compared with Normal Bladder Epithelia Identified by Microarray.
Gene Accession Number Description Fold Change P
Cell cycle– related genes
Cdc2a NM_019296 CDC2 homolog A* 2.7* .0250
Cdc20 U05341 CDC20 homolog* 4.6* .0040
Cdc23 BE111697 CDC23 (cell division cycle 23, yeast, homolog) (predicted)* 33.3* .0170
Cdc25B NM_133572 CDC25 homolog B 2.4 .0007
Cdc42ep5 AI599324 CDC42 effector protein (rho GTPase binding) 5 (predicted) 2.6 .0027
Cdca1 BG375704 Cell division cycle –associated 1 (predicted) 5.5 .0125
Cdca2 AW532628 Cell division cycle –associated 2 (predicted) 5.6 .0456
Cdca3 BF417638 Cell division cycle –associated 3 6.1 .0298
Ccna2 AA998516 Cyclin A2* 15.3* .0028
Ccnb1 X64589 Cyclin B1* 4.8* .0135
Ccnb2 AW253821 Cyclin B2* 6.5* .0041
Ccnd1 X75207 Cyclin D1* 8.8* .0151
Cdkn2a AF474976 Cyclin-dependent kinase inhibitor 2A (p16INK4a)* 8.7* .0310
Cdkn2c NM_131902 Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)* 3.7* .0005
Cdkn2d BI290067 Cyclin-dependent kinase inhibitor 2D* 2.2* .0053
Cdkn3 BE113362 Cyclin-dependent kinase inhibitor 3 (predicted)* 21.3* .0136
Mad2l1 AW143296 MAD2 (mitotic arrest deficient, homolog) – like 1 (yeast)* 2.0* .0050
Plk1 U10188 Polo-like kinase 1 (Drosophila)* 3.7* .0218
Plk4 BE109322 Polo-like kinase 4 (Drosophila) (predicted)* 2.5* .0059
Gadd45b BI287978 Growth arrest and DNA damage– inducible 45 b (predicted)* 2.7* .0007
Gadd45g AI599423 Growth arrest and DNA damage– inducible 45 g (predicted) 2.4 .0106
Gas5 BF287008 Growth arrest– specific 5 2.3 .0367
Gas7 AJ131902 Growth arrest– specific 7 2.3 .0305
Gap43 NM_017195 Growth-associated protein 43 2.1 .0167
Gdf1 BI289525 Growth differentiation factor 1 (predicted) 6.1 .0769
Bub1 BF388785 Budding uninhibited by benzimidazoles 1 homolog* 11.5* .0000
Bub1b BF557145 Budding uninhibited by benzimidazoles 1 homolog, b 7.9 .0074
Myc NM_012603 Myelocytomatosis viral oncogene homolog (avian) 2.5 .0077
Jundp NM_053894 2 Jun dimerization protein 2 3.8 .0017
Dusp6 NM_053883 Dual-specificity phosphatase 6* 2.4* .0245
Mki67 AI714002 Antigen identified by monoclonal antibody Ki-67* 20.8* .0010
Small G proteins
Racgap1 AI409259 Rac GTPase-activating protein 1* 17.8* .0146
Rad51 BI303370 RAD51 homolog (Saccharomyces cerevisiae)* 5.1* .0048
Rem2 BI296482 Rad- and gem-related GTP-binding protein 2 10.4 .0045
Rap2a AW251376 Rap2A-like protein 3.6 .0190
Rap2b NM_133410 RAP2B, member of RAS oncogene family 2.9 .0185
Rap2ip AI535169 Rap2-interacting protein* 4.8* .0221
Rin3 AI706777 Ras and Rab interactor 3 (predicted) 4.5 .0045
Rasgrp1 BI282819 RAS guanyl-releasing protein 1* 2.3* .0129
Rasgrp2 AW532114 RAS guanyl-releasing protein 2 (predicted) 2.1 .0247
Arhc AA891940 Ras homolog gene family, member C (predicted)* 2.5* .0003
Arhd AA955648 Ras homolog gene family, member D (predicted)* 2.1* .0020
Arhe AI103572 Ras homolog gene family, member E 2.8 .0158
Rnd1 AI144754 Rho family GTPase 1 (predicted) 5.1 .0405
Arhgap4 BE111827 Rho GTPase-activating protein 4 3.3 .0260
Arhgap8 AA945062 Rho GTPase-activating protein 8 2.3 .0025
BG377320 Rho guanine nucleotide exchange factor (GEF) 17 (predicted) 2.5 .0003
Arhgdib BF285771 Rho, GDP dissociation inhibitor (GDI) b (predicted) 3.7 .0040
Rock2 BI303031 Rho-associated coiled coil forming kinase 2 2.7 .0242
BG378261 Rhophilin, Rho GTPase binding protein 1 (predicted) 3.9 .0128
Oncogenes and tumor-suppressor genes
Akt1 NM_033230 V-akt murine thymoma viral oncogene homolog 1 1.5 .0077
Akt3 NM_031575 Thymoma viral proto-oncogene 3 2.4 .0255
Nf1 BM386570 Neurofibromatosis 1 3.1 .0168
Kit AI454052 V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 4.2 .0079
Maf NM_019318 V-maf musculoaponeurotic fibrosarcoma (avian) oncogene 2.7 .0024
Mafb AA900536 V-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 3.1 .0004
Ect2 AI578135 Ect2 oncogene (predicted)* 12.0* .0122
Fes BI289400 Feline sarcoma oncogene (predicted)* 3.4* .0068
Fyn AI230396 Fyn proto-oncogene 2.1 .0266
Myc NM_012603 Myelocytomatosis viral oncogene homolog (avian) 2.5 .0077
Ndr4 BG666709 N-myc downstream regulated 4 2.5 .0031
BM390283 Large tumor suppressor 2 (predicted) 2.3 .0010
Apoptosis
Birc2 NM_023987 Inhibitor of apoptosis protein 1* 3.3* .0077
Birc5 NM_022274 Baculoviral IAP repeat-containing 5 (Survivin) 3.6* .0500
Pawr U05989 PRKC, apoptosis, WT1, regulator 2.0 .0003
Casp1 D85899 Caspase 1* 2.7* .0173
Casp11 NM_053736 Caspase 11* 4.7* .0025
Casp12 NM_130422 Caspase 12 5.7 .0010
Pycard BI282953 Apoptosis-associated speck-like protein containing a CARD 2.1 .0047
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our finding of a relatively high proliferative index in lesions
derived from this model.
Annexin A1 (ANXA1) is a calcium-binding and phospho-
lipid-binding protein of the annexin superfamily that is found in
a wide range of organisms, including vertebrates, inverte-
brates, and plants. Overexpression of ANXA1 was found in
breast [20], stomach [21], pancreatic [22], and hepatic can-
cers [23], whereas underexpression of ANXA1 was recorded
in prostate [24,25], esophageal [25], and head and neck
[26] cancers. Thus, the role of ANXA1 in carcinogenesis
may occur in a tissue-specific manner. The exact function
of ANXA1 remains unknown. There are a number of possible
functions of ANXA1 in cancer development. For example,
ANXA1 serves as a substrate for EGFR [27] and is a steroid-
regulated protein [28]; thus, it has been linked with cell
proliferation and regulation of cell migration through the
regulation of the extracellular signal– regulated kinase/
mitogen-activated protein kinase (MAPK) signal transduction
pathway [29]. ANXA1 is also a critical mediator of apoptosis
[30]. Previous studies have also suggested that ANXA1
can serve as a gene target and gene maker for cancer treat-
ment, development, progression, and diagnosis. Expression
of ANXA1 significantly correlated with clinicopathological
features and survival in esophagus and esophagogastric
junction adenocarcinomas [31] and breast cancer [32]. Im-
munocytochemical detection of ANXA1 represents a simple,
inexpensive, highly sensitive, and specific assay for the
diagnosis of hairy cell leukemia [33].
The striking increases in ANXA1 levels observed in the
microarray, which was confirmed by RT-PCR, were then
examined by 2D gel analysis (Figure 3). Finally, based on
consistent increases observed in these various studies, we
performed IHC and similarly found striking increases in
annexin A1 expression. As can be seen in the IHC panel, a
strong response should allow us to examine the expression of
annexin A1 for identifying earlier lesions (dysplasias and
papillomas) or to potentially look for it in the urine of tumor-
bearing rats. Thus, the results with cyclin D1 and annexin A1
demonstrate methods that might allow one to combine re-
sults from gene expression and proteomic analyses.
We also found that COX-2 expression was increased
by roughly five times in RNA expressions in bladder tu-
mors. Interestingly, by IHC, we have shown that the highest
expression was not in epithelial cells but rather in endo-
thelial cells in the tumor [3]. Furthermore, we have found
that both celecoxib and a wide variety of nonsteroidal
anti-inflammatory drugs (NSAIDs) were highly effective in
blocking bladder tumor formation in this model [3]. This
parallels epidemiologic studies in humans showing the effi-
cacy of NSAIDs against bladder tumors. Interestingly, levels
of PPARc were reduced roughly by 3.5 times in microarrays.
We have recently found that PPARg expression was
Table 1. (continued )
Gene Accession Number Description Fold Change P
Apoptosis
Bcl11b BE116855 B-cell leukemia/lymphoma 11B (predicted) 4.0 .0006
Bcl2a1 NM_133416 B-cell leukemia/lymphoma 2 related protein A1* 5.6* .0033
Bcl3 AI411774 B-cell leukemia/lymphoma 3 (predicted)* 5.8* .0059
Bcl6 AI237606 B-cell leukemia/lymphoma 6 (predicted)* 3.6* .0014
Bok AI227742 Bcl-2– related ovarian killer protein* 2.2* .0040
Cebpd NM_013154 CCAAT/enhancer binding protein (C/EBP), y 2.9 .0002
Tnfsf13 AA800814 Tumor necrosis factor (ligand) superfamily, member 13 2.5 .0000
Tnfip6 AF159103 Tumor necrosis factor a induced protein 6 2.4 .0135
Tnfrsf11b NM_012870 Tumor necrosis factor receptor superfamily, member 11b* 3.9* .0012
Tnfrsf12a BI303379 Tumor necrosis factor receptor superfamily, member 12a 5.9 .0000
BI278479 Tumor necrosis factor, a-induced protein 2 (predicted) 2.8 .0024
Growth factors and related genes
Ctgf NM_022266 Connective tissue growth factor* 7.9* .0002
BF284634 Epidermal growth factor –containing fibulin-like extracellular matrix protein 1 3.9 .0015
Fgf13 NM_053428 Fibroblast growth factor 13 3.6 .0007
Fgfbp1 NM_022603 Fibroblast growth factor binding protein 1* 30.2* .0027
Hgf NM_017017 Hepatocyte growth factor 4.3 .0022
Hgfac BE119649 Hepatocyte growth factor activator 2.1 .0130
Hdgfrp3 BI283829 Hepatoma-derived growth factor, related protein 3 3.5 .0019
Igf1 M15481 Insulin-like growth factor 1 21.4 .0010
Igfbp3 NM_012588 Insulin-like growth factor binding protein 3* 3.2* .0000
Igfbp4 BE108969 Insulin-like growth factor binding protein 4 2.1 .0261
Igfbp7 AI233246 Insulin-like growth factor binding protein 7 3.0 .0000
Pdgfrb BM389426 Platelet-derived growth factor receptor, b polypeptide* 2.9* .0017
Pdgfa BE100812 Platelet-derived growth factor, a* 2.1* .0044
Pdgfc NM_031317 Platelet-derived growth factor, C polypeptide 3.0 .0054
Scgf AI576758 Stem cell growth factor 2.2 .0055
Tgfb1 NM_021578 Transforming growth factor, b 1 6.6 .0014
Tgfb2 NM_031131 Transforming growth factor, b 2* 5.9* .0021
Vegfc NM_053653 Vascular endothelial growth factor C 2.5 .0039
Most of the upregulated genes were small G proteins, apoptosis genes, cell cycle– related genes, oncogenes, and growth factors. Fold change is the ratio of the
mean gene expression values of tumors to the mean gene expression values of epithelia from the microarray.
*The genes were also found to be differentially expressed in mouse bladder tumors.
212 Altered Gene Expression in Rat Bladder Tumors Yao et al.
Neoplasia . Vol. 9, No. 3, 2007
decreased in tumors, as assessed by IHC procedures
(Grubbs and Fischer, data not shown). That indirectly reflects
our finding that the PPARg agonist rosiglitazone is a bladder
tumor promoter in this model. Twomechanistically significant
genes that we have previously demonstrated to exhibit
altered levels in rat bladder tumors are Fhit (fragile histidine
triad) and the IAP (inhibition of apoptosis protein) Survivin.
Fhit expression is often lost in a wide variety of human tumors
(e.g., lung, head and neck, and bladder). We have previously
shown that the Fhit gene is methylated in rat bladder tumors
and is associated with a decrease in FHIT protein expression
[34]. We also previously found an increased expression of
the IAP protein in rodent bladder tumors [35], as it is ex-
pressed in a variety of human tumors, including bladder.
These results reinforce the use of microarrays in looking for
the expression of specific ‘‘relevant genes,’’ in addition to its
more generalized use in looking for important pathways (Fig-
ure 4,A–D) or amuchwider variety of genes (Tables 1 and 2).
Table 2. Selected Genes Whose Expression Is Downregulated in Rat Bladder Tumors Compared with Normal Bladder Epithelia Identified by Microarray.
Gene Accession Number Description Fold Change P
Cell cycle– related genes
BE120410 Cyclin M1 (predicted) 2.7 .0110
Cdkn1c AI013919 Cyclin-dependent kinase inhibitor 1C, p57 5.8 .0000
Jundp1 NM_021865 Jun dimerization protein 1 2.1 .0024
Ppara NM_013196 Peroxisome proliferator-activated receptor a* 2.2* .0153
Pparg NM_013124 Peroxisome proliferator-activated receptor, g* 2.3* .0003
Small G proteins
Rab14 AA875010 RAB14, member RAS oncogene family 2.1 .0126
Rab27b NM_053459 RAB27B, member RAS oncogene family 3.3 .0000
Rab3c NM_133536 RAB3C, member RAS oncogene family 6.7 .0002
Rab40b AA924620 RAB40b, member RAS oncogene family (predicted) 3.2 .0001
BF284067 RAP1, GTPase-activating protein 1 (predicted) 3.6 .0000
Rasa3 AI237779 RAS p21 protein activator 3 2.6 .0014
RICS BE097238 RhoGAP involved in b-catenin–N-cadherin and NMDA receptor signaling (predicted) 2.1 .0005
AI547942 RhoGEF (Arhgef) and pleckstrin domain protein 1 2.2 .0009
Oncogenes and tumor-suppressor genes
AA900477 Vav2 oncogene (predicted) 2.3 .0002
Mycl1 BI300996 V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma–derived (avian)* 2.2* .0001
Ndrg2 NM_133583 N-myc downstream-regulated gene 2* 3.0* .0000
BE115673 Metastasis suppressor 1 (predicted) 4.7 .0013
Pak3 NM_019210 P21 (CDKN1A) –activated kinase 3 14.3 .0000
Pak4 BF404920 P21 (CDKN1A) –activated kinase 4 (predicted) 3.3 .0130
Wt1 NM_031534 Wilms tumor 1 2.7 .0278
Brca2 BF396613 Breast cancer 2 3.5 .0161
AI548958 HRAS-like suppressor (predicted) 2.5 .0015
Fhit NM_021774 Fragile histidine triad gene 1.6* .0107
Apoptosis
Dffa NM_053679 DNA fragmentation factor, a subunit* 2.0* .0060
LOC64171 NM_022303 Caspase recruitment domain protein 9 2.0 .0012
Ntrk1 NM_021589 Neurotrophic tyrosine kinase, receptor, type 1 3.5 .0391
Growth factors
BF418373 Epidermal growth factor – like protein 6 8.3 .0000
Fgf1 BI289840 Fibroblast growth factor 1* 2.8* .0006
FGFR2 L19107 Fibroblast growth factor receptor 2 2.9 .0384
BE112403 Fibroblast growth factor receptor substrate 2 (predicted) 2.0 .0042
BF396448 Insulin-like growth factor binding protein– like 1 2.2 .0036
BM384311 Platelet-derived growth factor receptor– like (predicted) 4.4 .0000
Others
Csnk1g1 AA957549 Casein kinase 1, g 1 2.1 .0058
Csnk1g3 AI176776 Casein kinase 1, g 3 2.5 .0147
BE107780 Casein kinase II, a 2, polypeptide (predicted) 2.3 .0012
Clpx BG371721 Caseinolytic protease X (Escherichia coli ) (predicted) 2.7 .0000
Cyp3a18 D38381 Cytochrome P450, 3a18 5.6 .0001
Cyp1a1 X00469 Cytochrome P450, family 1, subfamily a, polypeptide 1 22.1 .0053
Cyp11a1 NM_017286 Cytochrome P450, family 11, subfamily a, polypeptide 1 3.6 .0000
Cyp4a14 AA893326 Cytochrome P450, family 4, subfamily a, polypeptide 14 5.2 .0487
Lcmt1 BG381002 Leucine carboxyl methyltransferase 1 2.1 .0001
BE107055 Leucine-rich repeat-containing 28 (predicted) 2.0 .0001
AI716087 Leucine zipper transcription factor – like 1 (predicted) 2.0 .0000
BF412229 Leucine-rich and death domain–containing (predicted) 2.2 .0001
Lgi1 AI229354 Leucine-rich, glioma-inactivated 1 3.7 .0007
AI235414 RAR-related orphan receptor a (predicted) 2.4 .0000
BE110171 RAR-related orphan receptor g (predicted) 2.0 .0125
Downregulated genes include Rab subfamily genes, tumor-suppressor genes, casein kinases, cytochrome P450s, and RAR-related orphan receptor genes. Fold
change is the ratio of the mean gene expression values of tumors to the mean gene expression values of epithelia from the microarray.
*The genes were also found to be differentially expressed in mouse bladder tumors.
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The ras superfamily regulates many cellular processes,
such as cell cycle progression, actin cytoskeletal dynamics,
and membrane traffic. The transforming potential of ras is
due to a mutation, which, in human bladder tumors, occurs
in H-ras [36], although these rat tumors do not appear to
have mutations in ras genes. Alternatively, overexpression of
H-ras, K-ras, and N-ras transcripts has also been associated
with bladder tumor transition [37,38]. Guanine nucleotide
exchange factors (GEFs) stimulate Ras superfamily mem-
bers to exchange bound guanosine 5c-diphosphate (GDP)
for guanosine 5c-triphosphate (GTP), thereby increasing the
amount of active form [39].Rhomutations in tumors are quite
rare, but overexpression ismore common [40]. Dysregulation
of Rho family member activity probably also contributes to
human cancer in that some RhoGEFs act as oncogenes
[41], whereas RhoGAPs [42] act as tumor suppressors.
Reduced expression of RhoGDIs has recently been shown
to correlate with increasing invasive and metastatic abilities
in human bladder carcinoma cell lines [43,44]. We found that
RhoGAPs, RhoGEFs, and RhoGDIs were differentially ex-
pressed in rat bladder tumors.
Our results implicated many members of the integrin-
mediated cell adhesion pathway in bladder tumorigenesis.
Integrin a7, calpain 9, Pak3, rhodopsin (Rho), Rap1a, and
Vav2 underexpressed rat bladder tumors, whereas integrin
4, actin a1, caveolin-2, Fyn, Rock2, Mylk2, and Akt3 over-
expressed in rat bladder tumors. The small GTPase Rap1
is involved in several aspects of cell adhesion, including
integrin-mediated cell adhesion and cadherin-mediated cell
junction formation [45]. Rap1 regulates all integrins that are
associated with the actin cytoskeleton, such as integrins b1,
b2, and b3 [46]. Active Rap1 binds to a subset of Rac
Figure 2. Distribution of 2005 differentially expressed genes and ESTs by microarray analysis and real-time PCR confirmation for selected genes. (A) An overview
of the number of genes reveals fold changes different from those in normal bladder epithelia. (B) Comparison of fold change produced by microarray with the
relative expression ratio obtained from real-time PCR, with good concordance.
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GEFs, including Vav2 and Tiam1. Overexpressed Vav2 and
Tiam1 specifically require Rap1 to promote spreading, even
though Rac1 is activated independently of Rap1 [47]. Rac is
both required and sufficient to mediate Rap1-induced cell
spreading. Thus, integrin-mediated cell adhesion appears to
play a role in rat bladder tumorigenesis and progression.
Increased activity of another Ras effector, PI3-kinase, is
similarly associated with many types of human cancer. Be-
cause PI3-kinase is an immediate downstream effector of
Ras and EGFR, multiple pathways may contribute to the in-
creases in PI3-kinase activity observed in many bladder
cancers. PI3-kinase consistently prevents apoptosis in many
cell systems through activation of the Rac GTPase, possibly
through activation of NF-nB [48]. Thus, the activation of PI3-
kinase associated with excessive Ras activity may promote
oncogenesis by blunting apoptosis-inducing stimuli asso-
ciated with oncogenic transformation. RacGAPs stimulate
intrinsic GTPase activity, thus leading to Rac inactivation.
Rac and Rac-GEFs play key roles in the control of various
aspects of malignant transformation and metastatic cascade
in variousmodels [49], as well as in the control of mitogenesis
through its ability to regulate G1/S transition and cyclin
D1 expression [50–52]. Ect2 and RacGAP also regulate
the activation and function of Cdc42 in mitosis [53].
Finally, the differentially expressed genes between mouse
and rat bladder tumorswere compared.We found that, among
the 860 comparable genes between rats and mice, there were
280 genes that had the same tendency of expression in both
mouse and rat bladder tumors, accounting for about one third
of the genes. The majority of these genes are cell cycle–
related genes, ras small G proteins, and apoptosis-related
and growth factor–related genes. These results strongly
Figure 3. Confirmation of differentially expressed genes for both RNA and protein levels. (A) Comparison of fold change produced by microarray with the relative
expression ratio obtained from RT-PCR. (B) 2D protein gel electrophoresis indicates that annexin A1 protein is overexpressed in rat bladder cancers. (C) IHC
suggests that both annexin A1 and cyclin D1 are overexpressed in rat bladder cancers.
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indicated that both in mice and in rats, similar mechanisms
are involved in bladder tumorigenesis.
In human bladder tumors, low-grade papillary tumors
frequently show constitutive activation of the receptor tyro-
sine kinase/Ras pathway, exhibiting activating mutations in
H-ras and fibroblast growth factor receptor 3 (FGFR3) genes
[54,55]. In contrast, carcinoma in situ and invasive tumors
frequently show alterations in p53 and Rb genes and path-
ways [56,57]. The cell cycle is controlled by the p53 and Rb
pathways, with cells receiving extracellular growth signals
through the Ras/MAPK pathway. Previous studies have
shown that chemically induced rat bladder cancers typi-
cally have a mixed histology showing elements of both
transitional and squamous cells [3,4], with a relatively low
Figure 4. GenMAPP signaling pathways integrated into rat bladder tumorigenesis with a cutoff fold change of z 1.5 and P < .05. Yellow and blue indicates
overexpressed and underexpressed genes in tumor samples, respectively. Grey indicates that selection criteria were not met but the gene was represented in
the array. White boxes indicate that the gene was not present in the chip. (A) Apoptosis. (B) Cell cycle. (C) G1-to-S cell cycle control. (D) Integrin-mediated
cell adhesion.
A
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frequency of H-ras mutations and roughly 50% of these
tumors developing p53 mutations [58,59], similar to the per-
centage found in humans.
In recent years, genomewide expression profiling by the
use of microarray technology has provided new insights into
the gene expression patterns and dysregulation of genes
during bladder tumorigenesis. Gene expression profiles can
be used not only to elucidate the underlying molecular
mechanisms and pathways involved in bladder tumori-
genesis but also to make distinctions among different histo-
logic subtypes and to predict tumor recurrence and patient
survival. Gene expression array studies on human bladder
cancers have revealed a broad range of genes that are
differentially expressed during bladder tumorigenesis, pro-
gression, and invasion. Kawakami et al. [60] indicated that
genes involved in metabolism, transcription, cell adhesion/
Figure 4. (continued)
B
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surface, and cytoskeleton/cell membrane were significantly
differentially expressed in superficial and invasive bladder
tumors. Kim et al. examined gene expression patterns in the
development of bladder cancer from preneoplasia along
papillary and nonpapillary pathways and identified alterations
in seven gene clusters controlling proliferation, differentia-
tion, and apoptosis that were common for both papillary and
nonpapillary cancers. In contrast, genes controlling cellular
and stromal interactions were altered in nonpapillary cancer
[61]. Elsamman et al. also identified the significant upregu-
lation of 40 genes in cell differentiation and keratinization,
cell cycle, cell adhesion, transcription, and apoptosis asso-
ciated with superficial noninvasive bladder tumors, and the
significant upregulation of 34 genes related to extracellular
matrix degradation, immune responses, cell cycling, and
angiogenesis was associated with invasive bladder tumors
[62]. Dyrskjot et al. identified a 45-gene signature of bladder
tumor progression that was involved in regulating apoptosis,
Figure 4. (continued)
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cell differentiation, and cell cycle. BNIP3L, BIRC4, NCKAP1,
and BIRC6 genes, which are involved in the apoptotic cell
death pathway, were upregulated in the nonprogressing
group. Cdc25B, Cdc20, and MCM7 genes, which are in-
volved in regulating cell cycle and cell proliferation, were
upregulated in the progressing group [63]. Modlich et al.
also identified genes encoding transcription factors, protein
synthesis, and metabolism; cell cycle progression and dif-
ferentiation were overexpressed in superficial bladder tu-
mors, whereas transcripts for immune, extracellular matrix,
adhesion, peritumoral stroma, and muscle tissue compo-
nents; proliferation; and cell cycle controllers were upregu-
lated in invasive tumors [64]. In concordance with human
bladder tumors, in this study, we confirmed chemically in-
duced rat bladder cancers undergoing similar molecular
mechanisms and pathways during tumorigenesis and,
Figure 4. (continued)
D
Altered Gene Expression in Rat Bladder Tumors Yao et al. 219
Neoplasia . Vol. 9, No. 3, 2007
maybe, in progression. Genes involved in cell cycle, apop-
tosis, cell adhesion, transcription factors, and ras gene
pathway were significantly differentially expressed in rat
bladder cancers (Tables 1 and 2). These results suggested
that chemically induced rat bladder cancers can be used
to represent human bladder cancer. It is a good model for
studying the pathogenesis, progression, treatment, and pre-
vention of human bladder cancer.
In summary, we have determined the expression profiles
of genes differentially expressed during rat bladder tumori-
genesis. Our results suggest that EGFR-Ras pathway, cell
cycle, apoptosis, and integrin-mediated cell adhesion are
involved in bladder tumorigenesis. Our results also suggest
that commonmechanisms play important roles in both rat and
mouse tumorigeneses. Furthermore, certainty on identified
genes may suggest potential target molecules for preventing
cancer in this model.
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